menu search

CNTA / Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why

Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why
Centessa (CNTA) shares rise significantly in the past three months due to the encouraging progress in the development of its lead pipeline candidate, SerpinPC, which is currently in mid-late-stage studies. Read More
Posted: Sep 4 2023, 12:01
Author Name: Zacks Investment Research
Views: 112178

CNTA News  

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hemato

By GlobeNewsWire
November 2, 2023

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hemato

BOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that new data from an additional 52-w more_horizontal

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hemato

By GlobeNewsWire
November 2, 2023

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hemato

BOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that new data from an additional 52-w more_horizontal

Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why

By Zacks Investment Research
September 4, 2023

Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why

Centessa (CNTA) shares rise significantly in the past three months due to the encouraging progress in the development of its lead pipeline candidate, more_horizontal

Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress

By GlobeNewsWire
August 23, 2023

Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress

Oral presentation to include preclinical profile for ORX750, Centessa's first orexin agonist development candidate for the treatment of narcolepsy and more_horizontal

Should You Buy Centessa Pharmaceuticals (CNTA) Ahead of Earnings?

By Zacks Investment Research
March 23, 2023

Should You Buy Centessa Pharmaceuticals (CNTA) Ahead of Earnings?

Centessa Pharmaceuticals (CNTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings se more_horizontal

Wall Street Analysts Predict a 128% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know

By Zacks Investment Research
June 23, 2022

Wall Street Analysts Predict a 128% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know

The mean of analysts' price targets for Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) points to a 127.7% upside in the stock. While this highly so more_horizontal


Search within

Pages Search Results: